Literature DB >> 33656708

Difference of refractive status before and after cycloplegic refraction: the Lhasa Childhood Eye Study.

Lei Li1, Jing Fu2, Weiwei Chen1,3, Zhaojun Meng1, Yunyun Sun1, Han Su1, Yao Yao1, Wei Dai1.   

Abstract

PURPOSE: To compare the differences between cycloplegic and noncycloplegic refraction as well as associated factors in grade one students of primary schools, and explore the effectiveness of noncycloplegic refraction for refractive error screening. STUDY
DESIGN: Cross-sectional study.
METHODS: A school-based study of 1856 students was conducted in Lhasa, Tibetan Plateau, China. Cycloplegia was achieved with two drops of 1% cyclopentolate and 1 drop of Mydrin P at a 5-min interval. Autorefraction was performed under both cycloplegic and noncycloplegic conditions. Bland-Altman analysis, receiver operating characteristic curve analysis, univariate and multiple linear regression models were used for analysis.
RESULTS: Of the 1856 children enrolled, 1830 (98.60%) completed all procedures. The average age was 6.83 ± 0.46 years. 965 (52.73%) children were boys and 1737 (94.92%) were Tibetan. Overall, there was a significant difference between cycloplegic and noncycloplegic SE of 0.90 ± 0.76D (P < 0.001). However, the intra-class coefficient correlation (ICC) for cylinder between these two methods was high (ICC = 0.941, 95% CI, 0.935-0.946). Larger differences between cycloplegic and noncycloplegic SE were associated with hyperopic RE and higher cylindrical value (P < 0.001). The prevalence of myopia, emmetropia and hyperopia with and without cycloplegia was (3.93% vs 14.59%), (9.95% vs 45.8%) and (86.21% vs 39.56%), respectively. Myopia, emmetropia and hyperopia based on noncycloplegic refraction was defined as SE ≤ - 0.625D, - 0.625 < SE ≤ 0D, and SE > 0D, respectively.
CONCLUSIONS: Lack of cycloplegia leads to underestimation of hyperopia, with overestimation of myopia and emmetropia. Larger hyperopic refraction exhibited greater difference between cycloplegic and noncycloplegic refraction.

Entities:  

Keywords:  Children; Cycloplegic; Refractive status

Year:  2021        PMID: 33656708     DOI: 10.1007/s10384-021-00828-6

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  5 in total

1.  Cycloplegic refraction is the gold standard for epidemiological studies.

Authors:  Ian G Morgan; Rafael Iribarren; Akbar Fotouhi; Andrzej Grzybowski
Journal:  Acta Ophthalmol       Date:  2015-01-18       Impact factor: 3.761

2.  Visual impairment in school children in southern India.

Authors:  V Kalikivayi; T J Naduvilath; A K Bansal; L Dandona
Journal:  Indian J Ophthalmol       Date:  1997-06       Impact factor: 1.848

3.  Vision Screening of School Children by Teachers as a Community Based Strategy to Address the Challenges of Childhood Blindness.

Authors:  Gurvinder Kaur; Jacob Koshy; Satish Thomas; Harpreet Kapoor; Jiju George Zachariah; Sahiba Bedi
Journal:  J Clin Diagn Res       Date:  2016-04-01

4.  Accuracy of noncycloplegic refraction in primary school children in southern Thailand.

Authors:  Panrapee Funarunart; Supaporn Tengtrisorn; Pasuree Sangsupawanich; Prinda Siangyai
Journal:  J Med Assoc Thai       Date:  2009-06

5.  Refractive error, visual acuity and causes of vision loss in children in Shandong, China. The Shandong Children Eye Study.

Authors:  Jian Feng Wu; Hong Sheng Bi; Shu Mei Wang; Yuan Yuan Hu; Hui Wu; Wei Sun; Tai Liang Lu; Xing Rong Wang; Jost B Jonas
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  5 in total
  2 in total

1.  Paediatric vision screening in Urban Lhasa from the Tibetan Plateau of Southwest China.

Authors:  Weiwei Chen; Jing Fu; Ali Sun; Lei Li; Yunyun Sun; Zhaojun Meng
Journal:  Eye (Lond)       Date:  2022-06-06       Impact factor: 3.775

2.  Having One of the Fastest Growing Unmet Needs in Ophthalmology Reflected in Editorial Activities: Myopia.

Authors:  Kyoko Ohno-Matsui; Hendrik P N Scholl
Journal:  Ophthalmic Res       Date:  2021-12-02       Impact factor: 3.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.